Co-Trimoxazole Prophylaxis Is Associated with Reduced Risk of Incident Tuberculosis in Participants in the Swiss HIV Cohort Study | Zendy

Barbara Hasse | Zendy; A. Sarah Walker | Zendy; Jan Fehr | Zendy; Hansjakob Furrer | Zendy; Matthias Hoffmann | Zendy; Manuel Battegay | Zendy; Alexandra Calmy | Zendy; Jacques Fellay | Zendy; Caroline Di Benedetto | Zendy; Rainer Weber | Zendy; Bruno Ledergerber | Zendy

Open Access

Co-Trimoxazole Prophylaxis Is Associated with Reduced Risk of Incident Tuberculosis in Participants in the Swiss HIV Cohort Study

Author(s) -

Barbara Hasse,

A. Sarah Walker,

Jan Fehr,

Hansjakob Furrer,

Matthias Hoffmann,

Manuel Battegay,

Alexandra Calmy,

Jacques Fellay,

Caroline Di Benedetto,

Rainer Weber,

Bruno Ledergerber

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01868-13

Subject(s) - medicine , cohort , incidence (geometry) , tuberculosis , poisson regression , rate ratio , confidence interval , cumulative incidence , cohort study , hazard ratio , human immunodeficiency virus (hiv) , pediatrics , immunology , population , environmental health , physics , pathology , optics

Co-trimoxazole reduces mortality in HIV-infected adults with tuberculosis (TB), and in vitro data suggest potential antimycobacterial activity of co-trimoxazole. We aimed to evaluate whether prophylaxis with co-trimoxazole is associated with a decreased risk of incident TB in Swiss HIV Cohort Study (SHCS) participants. We determined the incidence of TB per 1,000 person-years from January 1992 to December 2012. Rates were analyzed separately in participants with current or no previous antiretroviral treatment (ART) using Poisson regression adjusted for CD4 cell count, sex, region of origin, injection drug use, and age. A total of 13,431 cohort participants contributed 107,549 person-years of follow-up: 182 patients had incident TB-132 (73%) before and 50 (27%) after ART initiation. The multivariable incidence rate ratios for cumulative co-trimoxazole exposure per year for persons with no previous ART and current ART were 0.70 (95% confidence interval [CI], 0.55 to 0.89) and 0.87 (95% CI, 0.74 to 1.0), respectively. Co-trimoxazole may prevent the development of TB among HIV-positive persons, especially among those with no previous ART.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research